開拓藥業(09939.HK)與康寧傑瑞製藥(09966.HK)合作進行產品臨床研究
開拓藥業(09939.HK)公布,與康寧傑瑞製藥(09966.HK)達成合作,共同推進ALK-1單克隆抗體GT90001聯合重組人源化PD-L1/CTLA-4雙特異性抗體KN046治療肝細胞癌等腫瘤的臨床研究。
根據協定,開拓藥業與康寧傑瑞製藥將成立聯合開發委員會並共同出資,就組合產品用於治療肝細胞癌及雙方共同確定的其他適應症的臨床前研究、臨床試驗申請、臨床試驗及註冊等環節進行合作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.